Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Agilon Health, Inc. (“Agilon”) (NYSE: AGL) common stock between April 15, 2021 and February 27, 2024, inclusive (the “Class Period”).
Agilon provides healthcare services to senior citizens, primarily through Medicare Advantage plans.
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Agilon suffered from systemic data and analytics gaps, and were unable to timely obtain and analyze data on members; (2) by relying on the delayed and incomplete data, Agilon was unable to accurately track, manage, report, or forecast medical margin and members’ medical costs; (3) Agilon could not effectively integrate payor systems and payor data with its platform and lacked the systems to reliably track, report, and forecast medical expenses; (4) due to the COVID-19 pandemic, Agilon saw increased medical costs for Medicare Advantage patients due to higher utilization; and (5) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On September 29, 2025, Defendants filed Answers to the Amended Complaint. This action is in the discovery phase and is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.